Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityActive in the last 2 years

Futang Li

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5064894276. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2025: 2 papers · 2026: 1 paper

Papers 3

  1. HOXC9 enhances cholesterol metabolism and malignancy in pancreatic ductal adenocarcinoma through ITGA10/FAK/PI3K/CREB-dependent HMGCR activation. Co-author DOI 10.1007/s00535-026-02457-7↗
  2. TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4. Co-author DOI 10.1016/j.drup.2024.101171↗
  3. ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer. Co-author DOI 10.1038/s41419-025-08061-6↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dijie Zheng · 3 shared papers, 2025–2026 · strength 0.84
  2. Zhiwei He · 2 shared papers, 2025 · strength 0.54
  3. Changhao Wu · 2 shared papers, 2025 · strength 0.54
  4. Xinghao Sun · 1 shared paper, 2026 · strength 0.30
  5. Liwen Chen · 1 shared paper, 2026 · strength 0.30
  6. Chao Yu · 1 shared paper, 2026 · strength 0.30
  7. Zhirui Zeng · 1 shared paper, 2025 · strength 0.28
  8. Chao Yu · 1 shared paper, 2025 · strength 0.28
  9. Chao Yu · 1 shared paper, 2025 · strength 0.26
  10. Yongning Li · 1 shared paper, 2025 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.